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Background: The extent of regional lymph node (LN) metastasis is
the most important factor in the evaluation of resectability and
prognosis of non-small cell lung cancer (NSCLC) to increase the
chance of complete cure. The authors attempted to deduce a group
of genes from the analysis of mRNA expression profiles of the
tumor tissues of NSCLC patients with or without LN metastasis, and
make a classification model for better prediction of LN metastasis.
Methods: The authors analyzed mRNA expression profiles of 79
NSCLC patients with or without LN metastasis, and deduced the
gene signature for the predictive model of LN metastasis in lung
cancer. The authors evaluated the predictive accuracy of each of four
algorithms by applying them to another set of 33 NSCLC patients.
Each algorithm’s accuracy was calculated by 10-fold cross-valida-
tion, and a combined model showed a level of accuracy that was
higher than any one of the better three component algorithms (i.e.,
ANN, DT, or NB). Avadis, SAS, ArrayXPath, and R-package were
the statistical analysis software packages used.
Results: The authors selected 949 genes using a classical permuta-
tion t test (p 0.01) and finally obtained a gene signature consisting
of 31 genes by adjustment of multiple-hypothesis testing. The LN
metastasis prediction model derived from the signature (31 genes)
and their characteristic interactions provided a predictive accuracy
of 84.85% when applied to a test set of 33 patients.
Conclusions: The authors have demonstrated that their gene signa-
ture developed by the expression profiling of mRNAs from the
primary tissue could predict the LN metastasis status of NSCLC.
Key Words: Cancer, Lung cancer, Diagnosis and staging, Lymph
node, Genetics.
(J Thorac Oncol. 2006;1: 622–628)
The optimal treatment of lung cancer relies on accuratedisease staging, which is based on tumor size, regional
nodal involvement, and the presence of metastasis. In partic-
ular, the extent of regional lymph node (LN) metastasis is the
most important prognostic factor for those patients with
resectable lung cancer. The cure rate following surgery is
considerably lower if there is any LN involvement (50% for
stage II disease and 30% for stage IIIA disease).1
Although computed tomography (CT) has been widely
used for the preoperative evaluation of tumor size and the
invasion of adjacent structures, many studies have shown that
CT has limitations for the staging of lung cancer because of
its low reliability for LN staging.2–5 The predictability of hilar
or peribronchial LN metastasis (N1 disease) is even lower
than that of mediastinal LN metastasis (N2 disease).6 Re-
cently, positron emission tomography (PET) using 18F-flu-
orodeoxyglucose has been reported to increase the diagnostic
accuracy for the differentiation of benign and malignant
lesions and to improve the identification of nodal metastasis.
However, it has been reported that 18F-fluorodeoxyglucose
PET is significantly less specific in depicting LN metastasis,
especially in geographic areas with endemic granulomatous
disease.7
Thus, to improve the cure rate, we need a more reliable
tool with which to assess preoperative LN metastasis. The
mechanisms by which malignant tumors leave the primary
tumor site, invade the lymphatic system, and metastasize to
the regional LNs are poorly understood. However, we are
able to acquire information concerning which genes are
differentially expressed according to such clinical parameters
as LN metastasis, distant metastasis, recurrence, and surviv-
al.8–14 Therefore, analysis of the differentially expressed
genes between LN metastatic tumors and nonmetastatic tu-
mors might allow researchers a better understanding of the
pathogenesis of LN metastasis.
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Obtaining mRNA expression profiles is an appropriate
method for measuring the levels of expression for all genes in
cancer. Along with clinical features, it may help to determine
prognostic subgroups of cancer. It has been reported that
cDNA microarray analysis could classify the subgroups of
lung adenocarcinomas according to gene expression profiles
and help create a risk index for survival.12 Moreover, studies
have used mRNA expression profiles as an adjunct to clinical
decision-making. For example, several recent reports have
suggested that gene expression profiles can predict recurrence
of Dukes’ stage B colon cancers,10 diagnose LN metastasis
from primary head and neck squamous cell carcinoma,15 and
predict the therapeutic response to docetaxel in patients with
breast cancer.16
In this study, we attempted to deduce a group of genes
from the analysis of mRNA expression profiles of the tumor
tissues of NSCLC patients with or without LN metastasis,
and create a classification model with the genes and an
appropriate algorithm. Then, we investigated whether the
model could predict the classification of regional LN metas-




Frozen tissues were collected from 302 patients among
a total of 923 patients with primary NSCLC who underwent
lung resection from January of 1995 to December of 2001 at
the Samsung Medical Center, where the following patients
were excluded: those with small cell or low-grade malig-
nancy histology such as adenoid cystic carcinoma or atypical
carcinoid, multiple pulmonary tumor nodules, preoperative
neoadjuvant treatment for pathologically proven mediastinal
LN metastases, chest or mediastinal invasion without LN
metastasis (T3N0), or malignant pleural effusion, and patients
who underwent an incomplete resection or who were without
mediastinal node dissection. Frozen tissues were further se-
lected by excluding the ones with less than 90% tumor cells
in the microdissected specimen and the ones with degraded
RNAs. As a result, frozen tissue specimens from 112 patients
were used for the study. The clinical profiles of those patients
consisting of 70 LN-negative patients and 42 LN-positive
patients are shown in Table 1. Histologic types of samples
were 48 adenocarcinomas, 58 squamous cell carcinomas, and
six large cell carcinomas; 46 patients showed recurrence.
Tissue Preparation and RNA Extraction
Systematic LN dissection was performed for all cases
by thoracotomy after routine mediastinoscopy. All the LNs
encountered were removed from the American Thoracic So-
ciety LN map areas 11, 10, 9, 8, 7, 4, 3, and 2 for the tumors
of the right lung; and from areas 11, 10, 9, 8, 7, 6, and 5 for
the tumors of the left lung.17 An average of six (range, five to
eight) mediastinal stations were dissected. All the surgically
removed tissues were immediately examined by experienced
pathologists. One or two pieces (5  5 mm) of tumor tissue
from the periphery of the tumor mass—to avoid the necrotic
region—were immediately stored at –80°C until retrieved for
the study.
The medical records were reviewed retrospectively,
and the available hematoxylin and eosin slides of the LNs
were reviewed by board-certified pathologists. A total of
2188 LNs were dissected from all the patients (the number of
LNs per patient, 21.3  10.6; range, 8–54), and 152 nodes
were positive for metastasis.
Three hundred two frozen tissues were microdissected
and lightly stained with hematoxylin to improve visualiza-
tion. After staining, the dried frozen tissues and the tumor
tissue containing normal cells that could not be microdis-
sected were excluded. One hundred sixty-three tissues were
used for RNA extraction, and the tissues having degraded
RNA were removed. Finally, 112 tumor tissue specimens
were used for the oligonucleotide microarray experiment.
Each microdissected specimen for the study contained more
than 90% tumor cells.
The microdissected tumor tissues were placed in 1 ml
of Trizol reagent (Life Technologies, Rockville, MD) and
immediately homogenized by vortexing. The total RNA was
isolated according to the Trizol reagent protocol. The quality
TABLE 1. Clinical Information of 112 Patients with Non-
small Cell Lung Cancer
Total
TNM Stage I TNM Stage II and III
N0 N N0 N
Histology
Adenocarcinoma 48 34 0 14 0
Squamous cell carcinoma 58 32 0 26 0
Large cell carcinoma 6 4 0 2 0
Smoking history
Nonsmoker 33 22 0 11 0
Smoker 77 46 0 31 0
Unknown 2 2 0 0 0
Sex
Female 29 20 0 9 0
Male 83 50 0 33 0
Differentiation
Well 19 15 0 4 0
Moderate 57 34 0 23 0
Poor 32 17 0 15 0
Unknown 4 4 0 0 0
Recurrence
Recurrent 46 24 0 22 0
Nonrecurrent 66 46 0 20 0
Current status
Alive 73 54 0 19 0
Dead 39 16 0 23 0
Operation Name
Pneumonectomy 19 2 10 2 5
Bilobectomy 7 3 3 0 1
Lobectomy 82 44 14 20 4
Wedge resection 4 1 2 0 1
TNM, tumor, node, metastasis.
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of the total RNA was analyzed by electrophoresis using a 1%
agarose gel containing 0.6 M formaldehyde and ethidium
bromide. The quantity of the total RNA was analyzed using
a Nanodrop spectrometer (Nanodrop Technologies, Rock-
land, DE).
Microarray Hybridization Analysis
Approximately 5 to 10 g of the total RNA from the
tumor tissues was used for the oligonucleotide microarray
analysis (Macrogen, Seoul, Korea), and the remainder was
used for reverse-transcriptase polymerase chain reaction
(PCR) or real-time PCR. The Macrogen Oligo Human 10K
microarray had been made by spotting 50-mer oligonucleo-
tide probes that represented 10,416 human genes, 8032
known genes, and 2076 expressed sequence tags.18 Each of
the 112 total RNAs was hybridized with a universal human
reference RNA (Stratagene, La Jolla, CA), and the oligonu-
cleotide microarray hybridizations, scanning, and normaliza-
tions were carried out as described previously.18
Validation of Array Data with Real-Time
Quantitative PCR
To validate the results of the oligonucleotide microar-
ray analysis, two genes and 16 randomly selected samples
were analyzed using real-time quantitative (RTQ) PCR
(PCR). The same 16 poly-A RNAs used in the microarray
analysis were reverse-transcribed with oligo(dT) priming
(Superscript II; Life Technologies). RTQ-PCR was per-
formed with specific primers for BCL-3 and GZMA. The
expression of the housekeeping gene GAPDH was used to
normalize for variances in the input cDNA. A relative stan-
dard curve representing three 10-fold dilutions of cDNA from
the mixed lung tissue samples (1:10:100:1000) was used for
the linear regression analyses of the unknown samples. The
cycling parameters used were 10 minutes at 95°C, 40 RTQ-
PCR cycles of 15 seconds at 95°C and 60 seconds at 60°C for
extension performed using an ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA)
with a TaqMan Universal PCR Master Mix (Roche, Branch-
burg, NJ). Real-time monitoring of the PCR products was
performed with the fluorescent dye FAM (Applied Biosys-
tems). The expression levels of the specific genes were
represented as their ratios against GAPDH. The PCR primer
pairs (5= to 3=) used for each gene were BCL-3 (catalogue No.
Hs00180403_m1; Applied Biosystems) and GZMA (cata-
logue No. Hs00196206_m1; Applied Biosystems). Relatively
high correlation between the results of microarray results and
those of RTQ-PCR allowed us to proceed with the subsequent
statistical analysis (data not shown).
Array Data Analysis and Classification
Modeling
The microarray hybridization images were scanned and
analyzed using ImaGene version 5.5 software (BioDiscovery,
El Segundo, CA), and the data were normalized by the
Lowess method, in which the value of the Cy-5/Cy-3 ratio
was log transformed with base 2. Hierarchical clustering was
performed to check whether the gene expression profiles of
tumor tissues were significantly distinguishable between the
presence and the absence of a patient’s LN metastasis. Then,
a permutation t test followed by multiple testing adjustment
with the Westfall-Young method was conducted to select
differentially expressed genes or signature.
Three algorithms (i.e., artificial neural network, deci-
sion tree, and naive Bayes) showed an acceptable level
(80%) of predictive accuracy in our case. However, to
develop a classification model with a higher accuracy of LN
metastasis prediction, we integrated a voting scheme in the
combination of those three algorithms, where a positive or
negative label for LN metastasis status was assigned when
two or three individual algorithms agreed.
Validation of the Classification Model
The classification model obtained from the above train-
ing set of 79 patients was tested for its predictive accuracy by
applying the test to a set of 33 new patients.
RESULTS
Location and Extent of LN Metastasis In
NSCLC
Among 79 patients in our training samples, 49 (62%)
were staged as pN0 and 30 (38%) showed lymphatic spread;
10 patients (33%) were staged as pN1 and 20 patients (67%)
as pN2 according to the 1997 TNM classification. In 33 new
samples for testing the developed model, 21 patients were
pN0 and 12 patients showed lymphatic spread (N1, four
patients; N2, eight patients) (Table 1). More than 2000 nodes
(n  2349), with an average of 21 LNs (range, 8–54) per
patient, were clinicopathologically analyzed for metastatic
infiltration. One hundred forty-eight LNs (6.3%) showed
metastatic involvement, whereas 2201 LNs (93.7%) were free
of tumor infiltration. LN involvement was present in 44% of
the patients with squamous cell carcinoma and in 33% of the
patients with large cell carcinoma. For patients with adeno-
carcinoma, the rate of LN involvement was 29%.
Distinctive Expression Profiles of Primary
Tumors with LN Metastatic Involvement
We prepared mRNA expression profiles derived from
primary tumors with or without LN metastatic involvement
using oligonucleotide microarray and checked for the global
discrepancy in gene expression between the two groups of
tumors using hierarchical clustering. The results demonstrate
that LN metastasis status was discriminated well, indicating
the possibility of selecting a group of genes involved in LN
metastasis (Figures 1 and 2).
Selection of LN Metastasis-Discriminating
Genes
To identify the differentially expressed genes between
patients with and without LN metastasis, we divided the 112
patients by stratified random sampling into two groups, 79
(49 without LN metastasis and 30 with LN metastasis) and 33
as the training set and the test set, respectively. Then, we
analyzed the mRNA expression profiles from the training set
and carried out the statistical analysis as described previously
to generate a gene signature. We found that the signature
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consisted of 31 genes (p  0.05) (i.e., 27 known genes and
four expressed sequence tags), and their characteristics are
summarized in Table 2.
Functional Classification of the Selected
Discriminatory Genes
To obtain a brief overview of the general functional
features of the LN metastasis-associated genes in NSCLC, we
performed the classification and analysis of functions for the
949 genes (p  0.01) that resulted from the t test before the
multiple testing adjustment using the ArrayXPath. The results
were deposited at the following website: http://biosvg.snubi.
org:8080/ArrayXPath/ArrayXPath_SonDaeSoon_949.html.
Specifically, 222 of 949 genes were identified in four public
pathway databases (GenMAPP, PharmGKB, KEGG, and
BioCarta) using ArrayXPath.19 The results are useful for
searching genes involved in cell proliferation, migration, and
survival that are essential to LN metastasis in cancer cells.
Thirty-one genes as the signature for LN metastasis
seem to be related to tumorigenesis and tumor suppression,
which is supported by the following facts on the component
genes: AATF, a recently identified human Rb-binding protein
that inhibits the Rb growth suppressing function20; BAT3,
related to apoptosis by caspase-3–mediated proteolytic acti-
vation21; and Cyb561, associated with senescence.22 Further
facts come from other genes: GPC4 binds FGF2 and modu-
lates fibroblast growth factor signal transduction23; Mcm3
expression appeared to be higher in cancer cells than in
normal proliferating cells of the uterine cervix and dysplastic
cells24; MUC5AC is a target gene of epidermal growth factor
receptor ligands in lung cancer cells, and up-regulation of this
gene goes through concomitant activation of the epidermal
growth factor receptor/Ras/Raf/extracellular signal-regulated
kinase-signaling pathway and Sp1 binding to their promot-
ers25; SOX6 may be a potential diagnostic marker for glio-
mas26; and TGIF2 may play an important role in the devel-
opment and/or progression of some ovarian tumors through a
mechanism of gene amplification.27
Development of the LN Metastasis Prediction
Model and Its Predictive Accuracy
Next, we developed the LN metastasis prediction
model using this gene signature and the modified algorithm
described previously. When we tested this model for its
predictive accuracy on the test set of 33 new patients, we
achieved a sensitivity of 83.33% and a specificity of 85.71%,
which is more accurate for the prediction of LN metastasis
than obtained by any of the algorithms (Table 3). Our LN
metastasis prediction model, which has been applied success-
fully to patients with their clinical information undisclosed,
showed another practical example of being a useful predic-
tion model as collectively structured parameters, not by one
or a few individual genes involved.
DISCUSSION
Because preoperative chemotherapy plus surgery al-
lows an increased median survival for patients with patho-
logically proven ipsilateral mediastinal lymph node metasta-
sis (pathological N2 stage IIIA),3,4 the neoadjuvant approach
has been examined for earlier disease, such as stage IB, IIA,
and IIB. However, contrary to the promising expectations, the
outcomes of the previous studies were disappointing. In the
phase II Bimodality Lung Oncology Team study performed
by Pisters et al., although 53 of 94 (56%) patients had a major
objective response after induction chemotherapy, only 81
patients (86%) had complete resection.28 Considering that the
candidates had T2N0, T1-2N1, or T3N0-1 staged NSCLC
and more than 95% had R0 resection (i.e., complete resection
with negative resection margins), this was too low a resection
rate, and the unnecessary delay of surgery may have been
attributable to unresectability. In addition, there was no re-
markable survival benefit identified at 1 and 2 years after
FIGURE 1. Supervised hierarchical clustering with average
linkage method. Patients’ samples are discriminated well by
the presence or absence of LN metastasis. The left side in
the heat map is LN metastasis-positive and the right side is
LN metastasis-negative.
FIGURE 2. Prediction flow of LN metastasis. Gene select
and construct model using 79 training samples measures
model performance for the test set (33 patients). Thirty-one
genes were selected as a signature from the training set, and
the resulting LN metastasis prediction model was evaluated
for its predictive accuracy by applying it to the test set.
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surgery, although the median survival had not yet been
reached for their report on the year 2000. Most prominently,
the authors mentioned that the interpretation of survival was
hampered by the relative nonhomogeneity of the clinical/
pathological stages of the treated patients.
In the Bimodality Lung Oncology Team study, despite
performing modern CT imaging and mediastinoscopy, clini-
cal staging was practically inaccurate, because only 16% of
patients showed an equivalent clinical and pathological
stage.28 If induction chemotherapy might be effective only for
patients with regional lymph node metastasis, surgery for
patients with stage I NSCLC might have been unnecessarily
delayed and the chance for survival was inadvertently taken
away.
Therefore, the accurate preoperative assessment of LN
involvement for patients with NSCLC is crucial for treatment
planning. Imaging modalities such as CT, magnetic reso-
nance imaging, and transesophageal endosonography provide
limited predictive value in differentiation between benign and
malignant nodes. McLoud et al. have shown that CT gives a
sensitivity of 64% and a specificity of 62% when extensive
sampling of nodes with a diameter of 1 cm as the upper limit
is allowed.2 PET and endoscopic ultrasound provide sensi-
tivities of 84% and 78% and specificities of 89% and 71%,
respectively, in diagnosis of LN metastasis in NSCLC.29
In the pretherapeutic LN staging of NSCLC, it has long
been assumed that there exists a correlation between node
size and metastatic infiltration. However, Prenzel et al.
showed a lack of a statistically significant relationship be-
tween the size of the LNs and the likelihood of malignancy in
a study of 2891 regional LNs from 256 patients.6 Similar
disappointing results were reported by Vogel et al. after
investigation of 162 mediastinal LNs in 83 patients.30 Despite
these findings, CT still has been the method of choice for
assessing LN metastasis in lung cancer.
In contrast, some researchers have tried to identify
patients with LN metastasis by using biological methods.
Analysis of serum vascular endothelial growth factor, micro-
satellite instability, or peanut agglutinin-binding carbohy-
drates in tumor suggested that these factors are related to
TABLE 2. Differentially Expressed Genes from an Analysis of mRNA Expression Profiles of 79 Patients with
Non-small Cell Lung Cancer as a Training Set (LN Metastasis Prediction Model Signature)
Gene Accession No. Gene Description Gene Symbol
AC005754 EST
AF216972 EST
AF309034 SRY (sex-determining region Y)-box 6 SOX6
ENSG00000084774 EST
NM_000486 Aquaporin 2 (collecting duct) AQP2
NM_000992 Ribosomal protein L29 RPL29
NM_001246 Ectonucleoside triphosphate diphosphohydrolase 2 ENTPD2
NM_001448 Glypican 4 GPC4
NM_001915 Cytochrome b-561 CYB561
NM_002262 Killer cell lectin-like receptor subfamily D, member 1 KLRD1
NM_002280 Keratin, hair, acidic, 5 KRTHA5
NM_002388 MCM3 minichromosome maintenance deficient 3 (Saccharomyces cerevisiae) MCM3
NM_003093 Small nuclear ribonucleoprotein polypeptide C SNRPC
NM_003365 Ubiquinol-cytochrome c reductase core protein I UQCRC1
NM_003481 Ubiquitin specific protease 5 (isopeptidase T) USP5
NM_003975 SH2 domain protein 2A SH2D2A
NM_004639 HLA-B associated transcript 3 BAT3
NM_004711 Synaptogyrin 1 SYNGR1
NM_012138 Apoptosis antagonizing transcription factor AATF
NM_014621 Homeo box D4 HOXD4
NM_014629 Rho guanine nucleotide exchange factor (GEF) 10 ARHGEF10
NM_015909 Neuroblastoma-amplified protein NAG
NM_016153 LW-1 LW-1
NM_018695 erbb2 interacting protein ERBB2IP
NM_020533 Mucolipin 1 MCOLN1
NM_021809 TGFB-induced factor 2 (TALE family homeobox) TGIF2
NM_022338 Chromosome 11 open reading frame 24 C11orf24
NM_030673 SEC13-like 1 (Saccharomyces cerevisiae) SEC13L1
NM_057090 Artemin ARTN
XM_039877 Mucin 5, subtype B, tracheobronchial MUC5B
XM_041585 EST
EST, expressed sequence tag.
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nodal metastasis in lung cancer.31–34 However, tumor metas-
tasis is a complex process that involves many interactions
between tumor cells and the extracellular matrix so that some
individual genetic changes discovered cannot be generalized
and are impractical to apply to clinical situations.
Extensive analysis of mRNA expression profiles or
protein expression profiles on a scale and with the sensitivity
unattainable by conventional techniques has been made pos-
sible by the improvement in high-throughput technologies.
For lung cancer, these clinical genomic or proteomic ap-
proaches have identified subgroups of tumors that differ in
terms of tumor type, histologic subclass, and patient survival,
allowing prediction of regional LN metastasis with a small
number of patients.12
The result of this study showed the possibility that gene
signatures from mRNA expression profiling can predict LN
metastasis with high accuracy for NSCLC. However, to be
used in clinical practice such as in planning of preoperative
chemotherapy, biopsy specimens should be collected from
the primary tumor lesion and then analyzed for gene expres-
sion. Successful application of such a technique has already
been reported by Borczuk et al.35
Although multigene signatures from mRNA expression
profiling can predict LN metastasis, the extent of the metas-
tasis, such as number of metastatic LNs or the delineation
between N1 and N2, cannot be identified because the distinc-
tion between N1 and N2 is made by anatomical, not biolog-
ical, criteria. Therefore, when preoperative analysis of gene
expression of the biopsy specimen suggests possible LN
metastasis, mediastinoscopy is imperative to discern N1 dis-
ease from N2 or N3 disease.
Even though we could select a group of genes from
mRNA expression profiling, some individual genes in the
group might not be useful for predicting LN metastasis as
mentioned earlier because of the complexity of most types of
cancer and the compound nature of gene functions. Thus, it is
desirable that gene sets representing the characteristic gene
expression profiles of LN metastasis are selected and their
interactions interpreted as a whole in a reasonably acceptable
manner. Furthermore, because our ultimate goal is prediction
of LN metastasis for new patients with the model developed
from the fixed data, the model’s robustness is essential for the
classification algorithm. For this reason, we decided to seek a
modified model constructed from a series of known classifi-
cation algorithms. We calculated the accuracy by 10-fold
cross-validation for each algorithm and then selected and
combined three independent algorithms (ANN, DT, and NB),
showing a greater than 85% accuracy. We found the robust-
ness in the resultant modified algorithm, which is good for
accuracy in sound judgment.
CONCLUSIONS
In our study with the long-term goal of validating our
gene set as a whole and not as individual genes for their
effective prospective discrimination of LN metastasis, we
TABLE 3. Performance of the LN Metastasis Prediction Model in Four Classification Algorithms
Classification Algorithm
10-Fold Cross-Validation in Training Set Prediction in Test Set of New Patients
mN0 mN Total Performance mN0 mN Total Performance
Support vector machine pN0 29 20 49 Sensitivity, 70.00%;
pN 9 21 30 specificity, 59.18%
accuracy, 63.29%
Total 38 41 79
Neural network
pN0 44 5 49 Sensitivity, 80.00%; pN0 18 3 21 Sensitivity, 58.33%;
pN 6 24 30 specificity, 89.80%
accuracy, 86.08%
pN 5 7 12 specificity, 85.75%
accuracy, 75.76%
Total 50 29 79 Total 23 10 33
Decision tree
pN0 46 3 49 Sensitivity, 83.33%; pN0 15 6 21 Sensitivity, 91.67%;
pN 5 25 30 specificity, 93.88%
accuracy, 89.87%
pN 1 11 12 specificity, 71.43%
accuracy, 78.79%
Total 51 28 79 Total 16 17 33
Naive Bayes
pN0 43 6 49 Sensitivity, 100%; pN0 17 4 21 Sensitivity, 75.00%;
pN 0 30 30 specificity, 87.76%
accuracy, 92.41%
pN 3 9 12 specificity, 80.95%
accuracy, 78.79%
Total 43 36 79 Total 20 13 33
Combined model (neural network decision pN0 44 5 49 Sensitivity, 93.33%; pN0 18 3 21 Sensitivity, 83.33%;
tree  naive Bayes) pN 2 28 30 specificity, 89.80%
accuracy, 91.14%
pN 2 10 12 specificity, 85.71%
accuracy, 84.85%
Total 46 33 79 Total 20 13 33
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selected genes by a modified algorithm that had been derived
by combining the last three of the above algorithms with a
voting scheme. Our selected gene sets and their modeled
interactions significantly improved the predictive accuracy of
LN metastasis in the training set of patients compared with
the other unmodified algorithms, and showed the prediction
with high accuracy in the test set of patients. For ideal
validation of this classification model, we should apply this
model to another set of mRNA expression profiles from a
new set of patients. This would provide us with an additional
chance to refine the current model to the integrated version,
allowing for even more accurate prediction.
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